Amgen Inc. Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31)
Amgen Inc. (AMGN) reported Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) of -$65.00 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet · last filed 2015-11-02
- Amgen Inc. derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2015-09-30 was -$65.00M, a 134.76% decline year-over-year.
- Amgen Inc. derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2015-06-30 was $44.00M, a 450.00% increase year-over-year.
- Amgen Inc. derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2015-03-31 was $168.00M, a 888.24% increase year-over-year.
- Amgen Inc. derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $86.00M, a 152.94% increase year-over-year.
- Amgen Inc. derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2014 was $298.00M, a 238.64% increase from fiscal 2013.
- Amgen Inc. derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2013 was $88.00M, a 486.67% increase from fiscal 2012.
- Amgen Inc. derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2012 was $15.00M.
- Amgen Inc. derivative instruments, gain (loss) recognized in other comprehensive income (loss), effective portion, net (deprecated 2018-01-31) for fiscal 2011 was -$51.00M, a 127.42% decline from fiscal 2010.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 3 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 6 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 9 month | Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2015-09-30 | -$65.00M 10-Q · filed 2015-11-02 | -$21.00M derived: sum of 2 quarters · filed 2015-11-02 | $147.00M 10-Q · filed 2015-11-02 | $233.00M derived: sum of 4 quarters · filed 2015-11-02 |
| 2015-06-30 | $44.00M 10-Q · filed 2015-08-05 | $212.00M 10-Q · filed 2015-08-05 | $298.00M derived: sum of 3 quarters · filed 2015-08-05 | $485.00M derived: sum of 4 quarters · filed 2015-11-02 |
| 2015-03-31 | $168.00M 10-Q · filed 2015-04-27 | $254.00M derived: sum of 2 quarters · filed 2015-04-27 | $441.00M derived: sum of 3 quarters · filed 2015-11-02 | $449.00M derived: sum of 4 quarters · filed 2015-11-02 |
| 2014-12-31 | $86.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $273.00M derived: sum of 2 quarters · filed 2015-11-02 | $281.00M derived: sum of 3 quarters · filed 2015-11-02 | $298.00M 10-K · filed 2015-02-19 |
| 2014-09-30 | $187.00M 10-Q · filed 2015-11-02 | $195.00M derived: sum of 2 quarters · filed 2015-11-02 | $212.00M 10-Q · filed 2015-11-02 | $246.00M derived: sum of 4 quarters · filed 2015-11-02 |
| 2014-06-30 | $8.00M 10-Q · filed 2015-08-05 | $25.00M 10-Q · filed 2015-08-05 | $59.00M derived: sum of 3 quarters · filed 2015-08-05 | $85.00M derived: sum of 4 quarters · filed 2015-08-05 |
| 2014-03-31 | $17.00M 10-Q · filed 2015-04-27 | $51.00M derived: sum of 2 quarters · filed 2015-04-27 | $77.00M derived: sum of 3 quarters · filed 2015-04-27 | $130.00M derived: sum of 4 quarters · filed 2015-04-27 |
| 2013-12-31 | $34.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $60.00M derived: sum of 2 quarters · filed 2015-02-19 | $113.00M derived: sum of 3 quarters · filed 2015-02-19 | $88.00M 10-K · filed 2015-02-19 |
| 2013-09-30 | $26.00M 10-Q · filed 2014-10-29 | $79.00M derived: sum of 2 quarters · filed 2014-10-29 | $54.00M 10-Q · filed 2014-10-29 | $90.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $53.00M 10-Q · filed 2014-08-05 | $28.00M 10-Q · filed 2014-08-05 | $64.00M derived: sum of 3 quarters · filed 2015-02-19 | -$25.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | -$25.00M 10-Q · filed 2014-04-30 | $11.00M derived: sum of 2 quarters · filed 2015-02-19 | -$78.00M derived: sum of 3 quarters · filed 2015-02-19 | $69.00M derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $36.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | -$53.00M derived: sum of 2 quarters · filed 2015-02-19 | $94.00M derived: sum of 3 quarters · filed 2015-02-19 | $15.00M 10-K · filed 2015-02-19 |
| 2012-09-30 | -$89.00M 10-Q · filed 2013-10-29 | $58.00M derived: sum of 2 quarters · filed 2013-10-29 | -$21.00M 10-Q · filed 2013-10-29 | $41.00M derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-06-30 | $147.00M 10-Q · filed 2013-08-06 | $68.00M 10-Q · filed 2013-08-06 | $130.00M derived: sum of 3 quarters · filed 2014-02-24 | $235.00M derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-03-31 | -$79.00M 10-Q · filed 2013-05-03 | -$17.00M derived: sum of 2 quarters · filed 2014-02-24 | $88.00M derived: sum of 3 quarters · filed 2014-02-24 | |
| 2011-12-31 | $62.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $167.00M derived: sum of 2 quarters · filed 2014-02-24 | -$51.00M 10-K · filed 2014-02-24 | |
| 2011-09-30 | $105.00M 10-Q · filed 2012-11-06 | -$113.00M 10-Q · filed 2012-11-06 | ||
| 2010-12-31 | $186.00M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |